stockrowTakeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.
- Revenue
- +1.71%
- EPS
- −4.35%
- Free cash flow
- +54.9%
- Total debt
- −7.28%
Quarter to September 2026, against a year earlier
Follow TAK
Alert me
Takeda Pharmaceutical Co. (TAK) Revenue
Takeda Pharmaceutical Co.'s revenue for fiscal 2026 was $29.7B, unchanged from fiscal 2025. Over the twelve months to 30 June 2026 it was $30.0B. Over the past ten years it has ranged from $15.0B (fiscal 2016) to $31.8B (fiscal 2022); the current reading is higher than 58% of that period. Takeda Pharmaceutical Co. ranks 1st of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2026 | $29.7B | (1.66%) |
| FY2025 | $30.2B | 2.78% |
| FY2024 | $29.4B | (1.29%) |
| FY2023 | $29.8B | (6.17%) |
| FY2022 | $31.8B | 5.67% |
| FY2021 | $30.1B | (0.72%) |
| FY2020 | $30.3B | 60.42% |
| FY2019 | $18.9B | 18.45% |
| FY2018 | $15.9B | (1.08%) |
| FY2017 | $16.1B | 7.38% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $7.7B | 0.64% |
| Jun 2025 | $7.6B | (1.23%) |
| Jun 2024 | $7.7B | 11.42% |
| Mar 2024 | $6.9B | (8.17%) |
| 25 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| TAK Takeda Pharmaceutical Co. | $30.0B |
| HLN Haleon PLC Sponsored ADR compare | $18.1B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $17.2B |
| VTRS Viatris Inc. compare | $14.7B |
| ZTS Zoetis Inc. compare | $9.5B |
| ELAN Elanco Animal Health Incorporated compare | $5.0B |
| NBIX Neurocrine Biosciences, Inc. compare | $3.7B |
| RDY Dr. Reddy's Laboratories Ltd compare | $3.3B |
| UTHR United Therapeutics Corporation compare | $3.2B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on TAK
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement